{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T06:10:41Z","timestamp":1794982241824,"version":"4.9.1"},"reference-count":298,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["KJZD20240903101312017"],"award-info":[{"award-number":["KJZD20240903101312017"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["KJZD20230923114706013"],"award-info":[{"award-number":["KJZD20230923114706013"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ijbiomac.2025.148054","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:32:23Z","timestamp":1759336343000},"page":"148054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"P2","title":["Multifaceted roles of heparin and its derivatives in inflammation and cancer: Mechanisms, clinical applications, and future directions"],"prefix":"10.1016","volume":"330","author":[{"given":"Xinling","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lige","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewen","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lirong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guorui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2025.148054_bb0005","first-page":"250","article-title":"The thromboplastic action of cephalin","volume":"41","author":"McLean","year":"1916","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0010","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3390\/ph16040584","article-title":"Heparin, low molecular weight heparin, and non-anticoagulant derivatives for the treatment of inflammatory lung disease","volume":"16","author":"Shute","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12672-025-01985-7","article-title":"Multifaceted role of heparin in oncology: from anticoagulation to anticancer mechanisms and clinical implications","volume":"16","author":"Koirala","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0020","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/19336918.2020.1767489","article-title":"The anti-cancer properties of heparin and its derivatives: a review and prospect","volume":"14","author":"Ma","year":"2020","journal-title":"Cell Adhes. Migr."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0025","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.matbio.2010.04.003","article-title":"Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer","volume":"29","author":"Casu","year":"2010","journal-title":"Matrix Biol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0030","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3390\/ijms18081808","article-title":"Crosstalk between DNA damage and inflammation in the multiple steps of carcinogenesis","volume":"18","author":"Kawanishi","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0035","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","volume":"42","author":"Galassi","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1161\/01.CIR.19.1.79","article-title":"Preparation of heparin and its use in the first clinical cases","volume":"19","author":"Best","year":"1959","journal-title":"Circulation"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0045","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0025-7125(16)30155-9","article-title":"Low-molecular-weight heparin","volume":"78","author":"Wolf","year":"1994","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0050","first-page":"5","article-title":"Production and chemical processing of low molecular weight heparins","volume":"25","author":"Linhardt","year":"1999","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0055","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/18877","article-title":"Synthesis of thrombin-inhibiting heparin mimetics without side effects","volume":"398","author":"Petitou","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0060","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1055\/s-2002-34309","article-title":"The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa","volume":"28","author":"Petitou","year":"2002","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0065","doi-asserted-by":"crossref","first-page":"24653","DOI":"10.1074\/jbc.M908930199","article-title":"Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis","volume":"275","author":"Lundin","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0070","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2005.01.034","article-title":"Selectively desulfated heparin inhibits P-selectin-mediated adhesion of human melanoma cells","volume":"229","author":"Wei","year":"2005","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0075","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10719-022-10081-9","article-title":"6-O-desulfated heparin attenuates myocardial ischemia\/reperfusion injury in mice through the regulation of miR-199a-5p\/klotho axis","volume":"39","author":"Wang","year":"2022","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40824-023-00420-8","article-title":"Nanoarchitectured conjugates targeting angiogenesis: investigating heparin-taurocholate acid conjugates (LHT7) as an advanced anti-angiogenic therapy for brain tumor treatment","volume":"27","author":"Kim","year":"2023","journal-title":"Biomater. Res."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0085","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.biomaterials.2017.05.026","article-title":"A heparin conjugate, LHbisD4, inhibits lymphangiogenesis and attenuates lymph node metastasis by blocking VEGF-C signaling pathway","volume":"139","author":"Choi","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0090","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.biomaterials.2012.11.020","article-title":"An apoptosis-homing peptide-conjugated low molecular weight heparin-taurocholate conjugate with antitumor properties","volume":"34","author":"Bae","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0095","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1039\/D3SC00260H","article-title":"Heparan sulfate glycomimetics via iterative assembly of \"clickable\" disaccharides","volume":"14","author":"Yang","year":"2023","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0100","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1021\/ma60071a044","article-title":"Studies on the conformation of heparin by 1H and 13C NMR spectroscopy","volume":"12","author":"Gatti","year":"1979","journal-title":"Macromolecules"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.carres.2014.06.023","article-title":"Re-visiting the structure of heparin","volume":"403","author":"Casu","year":"2015","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0110","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0008-6215(00)81050-2","article-title":"Further characterization of the antithrombin-binding sequence in heparin","volume":"100","author":"Thunberg","year":"1982","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0115","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1007\/s00216-014-7940-3","article-title":"USP compendial methods for analysis of heparin: chromatographic determination of molecular weight distributions for heparin sodium","volume":"406","author":"Mulloy","year":"2014","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0120","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low-molecular-weight heparins","volume":"337","author":"Weitz","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0125","first-page":"17","article-title":"Structural characterization of low molecular weight heparins","volume":"25","author":"Casu","year":"1999","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0130","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1742-1241.2002.tb11334.x","article-title":"Fondaparinux (Arixtra): a new anticoagulant","volume":"56","author":"Giangrande","year":"2002","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/bs.pmbts.2019.02.004","article-title":"The clinical use of fondaparinux: a synthetic heparin pentasaccharide","volume":"163","author":"Zhang","year":"2019","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.116824","article-title":"A heparin derivatives library constructed by chemical modification and enzymatic depolymerization for exploitation of non-anticoagulant functions","volume":"249","author":"Ji","year":"2020","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0145","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jconrel.2023.02.002","article-title":"Gastrointestinally absorbable lactoferrin-heparin conjugate with anti-angiogenic activity for treatment of brain tumor","volume":"355","author":"Hwang","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0150","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.scib.2024.03.064","article-title":"New therapeutic target NCF1-directed multi-bioactive conjugate therapies prevent preterm birth and adverse pregnancy outcomes","volume":"69","author":"Cheng","year":"2024","journal-title":"Sci. Bull."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.sbi.2015.05.007","article-title":"Current structural biology of the heparin interactome","volume":"34","author":"Pomin","year":"2015","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0160","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.ATV.9.1.21","article-title":"Molecular modeling of protein-glycosaminoglycan interactions","volume":"9","author":"Cardin","year":"1989","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0165","doi-asserted-by":"crossref","first-page":"19228","DOI":"10.1016\/S0021-9258(19)36503-2","article-title":"Comparative analysis of structurally defined heparin binding sequences reveals a distinct spatial distribution of basic residues","volume":"268","author":"Margalit","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0170","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1006\/abbi.1997.0147","article-title":"Pattern and spacing of basic amino acids in heparin binding sites","volume":"343","author":"Fromm","year":"1997","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042692","article-title":"The \"CPC clip motif\": a conserved structural signature for heparin-binding proteins","volume":"7","author":"Torrent","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0180","doi-asserted-by":"crossref","first-page":"20170490","DOI":"10.1098\/rsif.2017.0423","article-title":"Structural similarities in the CPC clip motif explain peptide-binding promiscuity between glycosaminoglycans and lipopolysaccharides","volume":"14","author":"Pulido","year":"2017","journal-title":"J. R. Soc. Interface"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0185","doi-asserted-by":"crossref","first-page":"19892","DOI":"10.1074\/jbc.M111.228114","article-title":"A systems biology approach for the investigation of the heparin\/heparan sulfate interactome","volume":"286","author":"Ori","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0190","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.trecan.2022.04.001","article-title":"Utilizing chemokines in cancer immunotherapy","volume":"8","author":"M\u00e4rkl","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0195","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41423-023-00974-6","article-title":"The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention, cell","volume":"20","author":"Cambier","year":"2023","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0200","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3389\/fimmu.2020.00483","article-title":"Targeting chemokine-glycosaminoglycan interactions to inhibit inflammation","volume":"11","author":"Crijns","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0205","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/jth.14369","article-title":"Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia","volume":"17","author":"Huynh","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0210","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.bpj.2020.04.012","article-title":"Platelet factor 4 interactions with short heparin oligomers: implications for folding and assembly","volume":"119","author":"Niu","year":"2020","journal-title":"Biophys. J."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101155","article-title":"Platelet factor 4 (PF4) and its multiple roles in diseases","volume":"64","author":"Liu","year":"2024","journal-title":"Blood Rev."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0220","doi-asserted-by":"crossref","first-page":"8288","DOI":"10.1074\/jbc.M008110200","article-title":"Characterization of the stromal cell-derived factor-1alpha-heparin complex","volume":"276","author":"Sadir","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0225","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1007\/s13277-015-3117-8","article-title":"Significantly inhibitory effects of low molecular weight heparin (Fraxiparine) on the motility of lung cancer cells and its related mechanism","volume":"36","author":"Zhong","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0230","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/sj.bjc.6603928","article-title":"Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo","volume":"97","author":"Mellor","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0235","doi-asserted-by":"crossref","first-page":"11721","DOI":"10.1074\/jbc.275.16.11721","article-title":"Examination of the function of RANTES, MIP-1alpha, and MIP-1beta following interaction with heparin-like glycosaminoglycans","volume":"275","author":"Ali","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0240","doi-asserted-by":"crossref","first-page":"15487","DOI":"10.1074\/jbc.273.25.15487","article-title":"Defining the interleukin-8-binding domain of heparan sulfate","volume":"273","author":"Spillmann","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0245","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00441-010-1034-0","article-title":"The complement system","volume":"343","author":"Sarma","year":"2011","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0250","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbagen.2005.08.003","article-title":"Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance","volume":"1726","author":"Yu","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0255","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/0161-5890(93)90079-Q","article-title":"Identification of multiple sites of interaction between heparin and the complement system","volume":"30","author":"Sahu","year":"1993","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0260","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3389\/fimmu.2020.01728","article-title":"Characterization of binding properties of individual functional sites of human complement factor H","volume":"11","author":"Haque","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0265","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fimmu.2014.00126","article-title":"Molecular interactions between complement factor H and its heparin and heparan sulfate ligands","volume":"5","author":"Perkins","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0270","doi-asserted-by":"crossref","first-page":"16451","DOI":"10.1074\/jbc.M114.627372","article-title":"Synergistic binding of vascular endothelial growth factor-A and its receptors to heparin selectively modulates complex affinity","volume":"290","author":"Teran","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0275","doi-asserted-by":"crossref","first-page":"14793","DOI":"10.1021\/bi9908641","article-title":"Identification and dynamics of a heparin-binding site in hepatocyte growth factor","volume":"38","author":"Zhou","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0280","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.3390\/molecules20046342","article-title":"Heparin\/heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use","volume":"20","author":"Chiodelli","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0285","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/med.21288","article-title":"FGF receptors: cancer biology and therapeutics","volume":"34","author":"Katoh","year":"2014","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0290","doi-asserted-by":"crossref","first-page":"8379","DOI":"10.1021\/bi9006379","article-title":"Compositional analysis of heparin\/heparan sulfate interacting with fibroblast growth factor.fibroblast growth factor receptor complexes","volume":"48","author":"Zhang","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0295","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1097-2765(00)00073-3","article-title":"Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization","volume":"6","author":"Schlessinger","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0300","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0959-440X(00)00258-X","article-title":"Role of heparan sulfate in fibroblast growth factor signalling: a structural view","volume":"11","author":"Pellegrini","year":"2001","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0305","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-015-0391-4","article-title":"Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy","volume":"14","author":"Ling","year":"2015","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114084","article-title":"Receptor tyrosine kinases and heparan sulfate proteoglycans: interplay providing anticancer targeting strategies and new therapeutic opportunities","volume":"178","author":"Lanzi","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0315","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1021\/bi8003999","article-title":"Role of the N- and C-terminal domains in binding of apolipoprotein E isoforms to heparan sulfate and dermatan sulfate: a surface plasmon resonance study","volume":"47","author":"Yamauchi","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0320","doi-asserted-by":"crossref","first-page":"25383","DOI":"10.1074\/jbc.M501589200","article-title":"Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism","volume":"280","author":"Lookene","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0325","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","article-title":"Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies","volume":"15","author":"Yamazaki","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0330","article-title":"Apolipoprotein E recognizes Alzheimer\u2019s disease associated 3-O sulfation of heparan sulfate","volume":"62","author":"Mah","year":"2023","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0335","doi-asserted-by":"crossref","first-page":"39138","DOI":"10.1074\/jbc.M104746200","article-title":"New insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E","volume":"276","author":"Libeu","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0340","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jconrel.2020.03.006","article-title":"Different kinetics for the hepatic uptake of lipid nanoparticles between the apolipoprotein E\/low density lipoprotein receptor and the N-acetyl-d-galactosamine\/asialoglycoprotein receptor pathway","volume":"322","author":"Sato","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0283358","article-title":"Combined action of albumin and heparin regulates lipoprotein lipase oligomerization, stability, and ligand interactions","volume":"18","author":"Risti","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0350","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.1073\/pnas.1900983116","article-title":"Lipoprotein lipase is active as a monomer","volume":"116","author":"Beigneux","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0355","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41573-020-00093-1","article-title":"The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans","volume":"20","author":"Smith","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0360","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1172\/JCI0214996","article-title":"Heparin\u2019s anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins","volume":"110","author":"Wang","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173778","article-title":"Review: inhibitory potential of low molecular weight heparin in cell adhesion; emphasis on tumor metastasis","volume":"892","author":"Ejaz","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0370","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood.V82.11.3253.3253","article-title":"Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation","volume":"82","author":"Nelson","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0375","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1172\/JCI1509","article-title":"Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents","volume":"101","author":"Koenig","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0380","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/1078-0432.CCR-05-1131","article-title":"Differential metastasis inhibition by clinically relevant levels of heparins\u2014correlation with selectin inhibition, not antithrombotic activity","volume":"11","author":"Stevenson","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0385","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.bcp.2006.05.006","article-title":"The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity","volume":"72","author":"Fritzsche","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0390","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1172\/JCI0214996","article-title":"Heparin\u2019s anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L-and P-selectins","volume":"110","author":"Wang","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0395","doi-asserted-by":"crossref","first-page":"6156","DOI":"10.1021\/bi602347g","article-title":"Kinetic analysis of heparin and glucan sulfates binding to P-selectin and its impact on the general understanding of selectin inhibition","volume":"46","author":"Simonis","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0400","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.matbio.2017.11.012","article-title":"Heparin-fibronectin interactions in the development of extracellular matrix insolubility","volume":"67","author":"Raitman","year":"2018","journal-title":"Matrix Biol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0405","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1038\/s41467-018-04525-w","article-title":"Laminin heparin-binding peptides bind to several growth factors and enhance diabetic wound healing","volume":"9","author":"Ishihara","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0410","doi-asserted-by":"crossref","first-page":"19393","DOI":"10.1074\/jbc.272.31.19393","article-title":"Identification of the antithrombin III heparin binding site","volume":"272","author":"Ersdal-Badju","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0415","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1111\/jth.15052","article-title":"Anticoagulant and signaling functions of antithrombin","volume":"18","author":"Rezaie","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0420","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/med.21489","article-title":"Heparin mimetics with anticoagulant activity","volume":"38","author":"Nahain","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0425","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10719-024-10172-9","article-title":"Inhibition of sulfated glycans on the binding of dengue virus envelope protein to heparin","volume":"41","author":"Yang","year":"2024","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0430","doi-asserted-by":"crossref","first-page":"8911","DOI":"10.1128\/JVI.00672-08","article-title":"Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942)","volume":"82","author":"Schmidt","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0435","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.7861\/clinmed.2020-0351","article-title":"Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19","volume":"20","author":"Conzelmann","year":"2020","journal-title":"Clin. Med. (Lond.)"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2020.461378","article-title":"Capture and purification of human immunodeficiency virus-1 virus-like particles: convective media vs porous beads","volume":"1627","author":"Pereira Aguilar","year":"2020","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0445","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.prot095620","article-title":"Purification of recombinant adeno-associated virus 2 (rAAV2) by heparin column affinity chromatography","volume":"2020","author":"Auricchio","year":"2020","journal-title":"Cold Spring Harb Protoc"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0450","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fcimb.2016.00173","article-title":"Different use of cell surface glycosaminoglycans as adherence receptors to corneal cells by Gram positive and Gram negative pathogens","volume":"6","author":"Garc\u00eda","year":"2016","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0455","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/ijms19010207","article-title":"Synthesized heparan sulfate competitors attenuate Pseudomonas aeruginosa lung infection","volume":"19","author":"Lor\u00e8","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0460","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ijbiomac.2017.03.036","article-title":"Heparin depolymerization by immobilized heparinase: a review","volume":"99","author":"Bhushan","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0465","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nm1087","article-title":"Cancer genes and the pathways they control","volume":"10","author":"Vogelstein","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0470","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1002\/ijc.33398","article-title":"Epigenetic regulation of cancer stem cell formation and maintenance","volume":"148","author":"French","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0475","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrrev.2020.108308","article-title":"Life style factors, tumor cell plasticity and cancer stem cells","volume":"784","author":"Chiodi","year":"2020","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0485","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10555-020-09915-5","article-title":"Molecular epidemiology and diagnostics of KRAS mutations in human cancer","volume":"39","author":"Timar","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0490","doi-asserted-by":"crossref","first-page":"8102","DOI":"10.3390\/ijms22158102","article-title":"Inflammation, extracellular matrix remodeling, and proteostasis in tumor microenvironment","volume":"22","author":"Marozzi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0495","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3332\/ecancer.2017.721","article-title":"Dual role of inflammatory mediators in cancer","volume":"11","author":"Shrihari","year":"2017","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0500","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s42255-020-00317-z","article-title":"Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism","volume":"3","author":"Elia","year":"2021","journal-title":"Nat. Metab."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0505","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/149185","article-title":"Chronic inflammation and cytokines in the tumor microenvironment","volume":"2014","author":"Landskron","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0510","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1002\/ijc.23192","article-title":"Chronic inflammation and oxidative stress in human carcinogenesis","volume":"121","author":"Federico","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0515","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/med.22018","article-title":"Dissecting the pleiotropic roles of reactive oxygen species (ROS) in lung cancer: from carcinogenesis toward therapy","volume":"44","author":"Hou","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0520","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nri1703","article-title":"NF-kappaB: linking inflammation and immunity to cancer development and progression","volume":"5","author":"Karin","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0525","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u03baB in biology and targeted therapy: new insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0530","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nri.2017.142","article-title":"NF-\u03baB, inflammation, immunity and cancer: coming of age","volume":"18","author":"Taniguchi","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0535","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1002\/jcp.27411","article-title":"Cyclooxygenase-2 in cancer: a review","volume":"234","author":"Hashemi Goradel","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0540","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12935-015-0260-7","article-title":"Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity","volume":"15","author":"Liu","year":"2015","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0545","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","article-title":"Targeting NF-\u03baB pathway for the therapy of diseases: mechanism and clinical study","volume":"5","author":"Yu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0550","first-page":"160","article-title":"Increased IL-1\u03b1 expression is correlated with bladder cancer malignant progression","volume":"19","author":"Yao","year":"2023","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0555","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1042\/CS20191211","article-title":"Emerging roles for the IL-6 family of cytokines in pancreatic cancer","volume":"134","author":"van Duijneveldt","year":"2020","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0560","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0565","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","article-title":"The two faces of IL-6 in the tumor microenvironment","volume":"26","author":"Fisher","year":"2014","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0570","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/ijc.29297","article-title":"Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients","volume":"136","author":"Jiang","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0575","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41577-021-00624-w","article-title":"The interplay of immunology and cachexia in infection and cancer","volume":"22","author":"Baazim","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0580","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0585","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3390\/cancers10070219","article-title":"Role of p53 in the regulation of the inflammatory tumor microenvironment and tumor suppression","volume":"10","author":"Uehara","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0590","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41417-024-00811-6","article-title":"NF-\u03baB role on tumor proliferation, migration, invasion and immune escape","volume":"31","author":"Khan","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0595","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/sj.onc.1209237","article-title":"K-ras activation generates an inflammatory response in lung tumors","volume":"25","author":"Ji","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0600","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/icb.2013.58","article-title":"The interplay between pathogen-associated and danger-associated molecular patterns: an inflammatory code in cancer?","volume":"91","author":"Escamilla-Tilch","year":"2013","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0605","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-032414-112043","article-title":"Innate immune recognition of cancer","volume":"33","author":"Woo","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0610","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1126\/science.aal5240","article-title":"Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer","volume":"358","author":"Bullman","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0615","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/cmi.2013.59","article-title":"TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells","volume":"11","author":"Fang","year":"2014","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0620","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40425-019-0545-9","article-title":"Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity","volume":"7","author":"Kashyap","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0625","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","article-title":"Targeting immunogenic cell stress and death for cancer therapy","volume":"23","author":"Galluzzi","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0630","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-020-00267-8","article-title":"Targeting chemokines\/chemokine receptors: a promising strategy for enhancing the immunotherapy of pancreatic ductal adenocarcinoma","volume":"5","author":"Gong","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0635","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1002\/cam4.3014","article-title":"Chemokines and chemokine receptors: a new strategy for breast cancer therapy","volume":"9","author":"Liu","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0640","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fonc.2016.00093","article-title":"Targeting selectins and their ligands in cancer","volume":"6","author":"Natoni","year":"2016","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0645","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3389\/fimmu.2019.02120","article-title":"Altered cell adhesion and glycosylation promote cancer immune suppression and metastasis","volume":"10","author":"L\u00e4ubli","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0650","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fonc.2014.00028","article-title":"Altered tumor-cell glycosylation promotes metastasis","volume":"4","author":"H\u00e4uselmann","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0655","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1517\/14728222.2013.841140","article-title":"Targeting selectins for the treatment of inflammatory diseases","volume":"18","author":"Impellizzeri","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0660","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1517\/14728222.11.11.1473","article-title":"Targeting selectins and selectin ligands in inflammation and cancer","volume":"11","author":"Barthel","year":"2007","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0665","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10585-012-9461-9","article-title":"Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model","volume":"29","author":"Sudha","year":"2012","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0670","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s12253-012-9531-y","article-title":"Activated platelets interact with lung cancer cells through P-selectin glycoprotein ligand-1","volume":"18","author":"Gong","year":"2012","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0675","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6138145","article-title":"The interaction of selectins and PSGL-1 as a key component in thrombus formation and cancer progression","volume":"2017","author":"Kappelmayer","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0680","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1158\/0008-5472.CAN-05-3121","article-title":"L-selectin facilitation of metastasis involves temporal induction of Fut7-dependent ligands at sites of tumor cell arrest","volume":"66","author":"L\u00e4ubli","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0685","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1182\/blood.V88.9.3259.bloodjournal8893259","article-title":"Selectins and their ligands: current concepts and controversies","volume":"88","author":"Kansas","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0690","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1016-8478(23)24495-7","article-title":"P-selectin-mediated acute inflammation can be blocked by chemically modified heparin, RO-heparin","volume":"19","author":"Gao","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0695","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bjh.14303","article-title":"Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion","volume":"175","author":"Telen","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0700","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3390\/biom14091078","article-title":"The preventive and therapeutic effects of acute and severe inflammatory disorders with heparin and heparinoid","volume":"14","author":"Song","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.105692","article-title":"Protein kinase C signaling \u201cin\u201d and \u201cto\u201d the nucleus: master kinases in transcriptional regulation","volume":"300","author":"Kazanietz","year":"2024","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0710","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.3390\/cancers14051104","article-title":"Targeting protein kinase C for cancer therapy","volume":"14","author":"He","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0715","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.3390\/cancers14215425","article-title":"Protein kinase C (PKC) isozymes as diagnostic and prognostic biomarkers and therapeutic targets for cancer","volume":"14","author":"Kawano","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0720","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0725","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1158\/1078-0432.CCR-06-1832","article-title":"Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors","volume":"13","author":"Edelman","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0730","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3390\/ijms20061498","article-title":"The role of tyrosine phosphorylation of protein kinase C delta in infection and inflammation","volume":"20","author":"Yang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0735","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/SHK.0000000000001247","article-title":"Protein kinase C-delta (PKC\u03b4) tyrosine phosphorylation is a critical regulator of neutrophil-endothelial cell interaction in inflammation","volume":"51","author":"Soroush","year":"2019","journal-title":"Shock"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0740","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1096\/fj.201701099","article-title":"PKC\u03b4 inhibition as a novel medical countermeasure for radiation-induced vascular damage","volume":"32","author":"Soroush","year":"2018","journal-title":"FASEB J."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0745","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/(SICI)1097-4652(199707)172:1<69::AID-JCP8>3.0.CO;2-B","article-title":"Mechanisms of inhibition by heparin of PDGF stimulated MAP kinase activation in vascular smooth muscle cells","volume":"172","author":"Pukac","year":"1997","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0750","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1091\/mbc.1.5.435","article-title":"Heparin inhibits c-fos and c-myc mRNA expression in vascular smooth muscle cells","volume":"1","author":"Pukac","year":"1990","journal-title":"Cell. Regul."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0755","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1083\/jcb.109.6.3147","article-title":"Heparin selectively inhibits a protein kinase C-dependent mechanism of cell cycle progression in calf aortic smooth muscle cells","volume":"109","author":"Castellot","year":"1989","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0760","doi-asserted-by":"crossref","first-page":"25928","DOI":"10.1074\/jbc.271.42.25928","article-title":"Protein kinase C \u03b1 expression is required for heparin inhibition of rat smooth muscle cell proliferation in vitro and in vivo","volume":"271","author":"Herbert","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0765","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0014-5793(98)00073-8","article-title":"Heparin inhibits phorbol ester-induced ornithine decarboxylase gene expression in endothelial cells","volume":"423","author":"Pintus","year":"1998","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0770","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0014-5793(99)00438-X","article-title":"Heparin down-regulates the phorbol ester-induced protein kinase C gene expression in human endothelial cells: enzyme-mediated autoregulation of protein kinase C-\u03b1 and-\u03b4 genes","volume":"449","author":"Pintus","year":"1999","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0775","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.canlet.2011.08.016","article-title":"Low molecular weight heparin inhibits melanoma cell adhesion and migration through a PKCa\/JNK signaling pathway inducing actin cytoskeleton changes","volume":"312","author":"Chalkiadaki","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0780","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.2174\/138161207781039742","article-title":"Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate","volume":"13","author":"Vlodavsky","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0785","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41523-021-00277-x","article-title":"Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer","volume":"7","author":"Zahavi","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0790","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3389\/fonc.2019.01316","article-title":"Heparanase: a challenging cancer drug target","volume":"9","author":"Coombe","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0795","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3390\/cells12060891","article-title":"Heparanase modulates chromatin accessibility","volume":"12","author":"Li","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0800","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1074\/jbc.M111.271346","article-title":"Heparanase induces signal transducer and activator of transcription (STAT) protein phosphorylation: preclinical and clinical significance in head and neck cancer","volume":"287","author":"Cohen-Kaplan","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0805","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/glycob\/cwu119","article-title":"Antitumor properties of a new non-anticoagulant heparin analog from the mollusk Nodipecten nodosus: effect on P-selectin, heparanase, metastasis and cellular recruitment","volume":"25","author":"Gomes","year":"2015","journal-title":"Glycobiology"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0810","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1535-7163.MCT-18-0417","article-title":"Necuparanib, a multitargeting heparan sulfate mimetic, targets tumor and stromal compartments in pancreatic cancer","volume":"18","author":"MacDonald","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0815","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.matbio.2018.08.005","article-title":"The heparanase inhibitor PG545 is a potent anti-lymphoma drug: mode of action","volume":"77","author":"Weissmann","year":"2019","journal-title":"Matrix Biol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0820","doi-asserted-by":"crossref","first-page":"C1184","DOI":"10.1152\/ajpcell.00269.2013","article-title":"Heparanase induces inflammatory cell recruitment in vivo by promoting adhesion to vascular endothelium","volume":"306","author":"Lever","year":"2014","journal-title":"Am. J. Phys. Cell Physiol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0825","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575047","article-title":"Increased plasma heparanase activity in COVID-19 patients","volume":"11","author":"Buijsers","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119376","article-title":"Heparin prevents in vitro glycocalyx shedding induced by plasma from COVID-19 patients","volume":"276","author":"Potje","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0835","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/SHK.0000000000002021","article-title":"High heparanase level in survivors of COVID-19-indicator of vascular and pulmonary recovery?","volume":"58","author":"Neb","year":"2022","journal-title":"Shock"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0840","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.matbio.2023.07.003","article-title":"The extracellular matrix-immune microenvironment crosstalk in cancer therapy: challenges and opportunities","volume":"121","author":"Closset","year":"2023","journal-title":"Matrix Biol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0845","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.3390\/ijms20236008","article-title":"Cytokines in inflammatory disease","volume":"20","author":"Kany","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104311","article-title":"The cytokines in tumor microenvironment: from cancer initiation-elongation-progression to metastatic outgrowth","volume":"196","author":"Pradhan","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0855","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/pharmrev.122.000684","article-title":"Pharmacology of heparin and related drugs: an update","volume":"75","author":"Hogwood","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0860","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1182\/blood.V84.12.4008.bloodjournal84124008","article-title":"Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes","volume":"84","author":"Trinchieri","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0865","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/cancers13020167","article-title":"IL-12 family cytokines in cancer and immunotherapy","volume":"13","author":"Mirlekar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0870","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cyto.2018.04.014","article-title":"The localisation of the heparin binding sites of human and murine interleukin-12 within the carboxyterminal domain of the P40 subunit","volume":"110","author":"Garnier","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0875","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.1038\/s41598-017-05382-1","article-title":"Modulation of Interleukin-12 activity in the presence of heparin","volume":"7","author":"Jayanthi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0880","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.3390\/jcm9082666","article-title":"The antitumor effect of heparin is not mediated by direct NK cell activation","volume":"9","author":"Rossi","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0885","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1074\/jbc.RA118.006193","article-title":"Molecular mechanisms of heparin-induced modulation of human interleukin 12 bioactivity","volume":"294","author":"Nguyen","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0890","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/imm.13486","article-title":"Pathogenetic role and clinical significance of interleukin-1\u03b2 in cancer","volume":"168","author":"Malkova","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0895","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0900","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting STAT3 in cancer immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0905","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.4049\/jimmunol.165.10.5671","article-title":"Characterization of the heparin-binding properties of IL-6","volume":"165","author":"Mummery","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0910","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910730","article-title":"Molecular mechanism of the anti-inflammatory action of heparin","volume":"22","author":"Litov","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0915","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3390\/ph17030371","article-title":"The effect of heparin and other exogenous glycosaminoglycans (GAGs) in reducing IL-1\u03b2-induced pro-inflammatory cytokine IL-8 and IL-6 mRNA expression and the potential role for reducing inflammation","volume":"17","author":"Jafri","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0920","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2567.2011.03485.x","article-title":"Mechanisms regulating chemokine receptor activity","volume":"134","author":"Bennett","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0925","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1158\/1078-0432.CCR-09-2329","article-title":"CXCL12 (SDF-1)\/CXCR4 pathway in cancer","volume":"16","author":"Teicher","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0930","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.2174\/0929867326666191113113110","article-title":"The CXCL12-CXCR4 signaling axis plays a key role in cancer metastasis and is a potential target for developing novel therapeutics against metastatic cancer","volume":"27","author":"Yang","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0935","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/med.22011","article-title":"CXCR4\/CXCL12 axis: \u201cold\u201d pathway as \u201cnovel\u201d target for anti-inflammatory drug discovery","volume":"44","author":"Lu","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0940","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1158\/1078-0432.CCR-06-1987","article-title":"Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids?","volume":"13","author":"Harvey","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0945","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s10637-010-9578-0","article-title":"Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer","volume":"30","author":"Ma","year":"2012","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0950","doi-asserted-by":"crossref","first-page":"10018","DOI":"10.1074\/jbc.M608796200","article-title":"Structural and functional basis of CXCL12 (stromal cell-derived factor-1\u03b1) binding to heparin","volume":"282","author":"Murphy","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0955","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.biomaterials.2016.01.058","article-title":"Multi-stage inhibition in breast cancer metastasis by orally active triple conjugate, LHTD4 (low molecular weight heparin-taurocholate-tetrameric deoxycholate)","volume":"86","author":"Alam","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0960","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.170168","article-title":"Heparin-bound chemokine CXCL8 monomer and dimer are impaired for CXCR1 and CXCR2 activation: implications for gradients and neutrophil trafficking","volume":"7","author":"Joseph","year":"2017","journal-title":"Open Biol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0965","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/cac2.12010","article-title":"CXCL5\/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target","volume":"40","author":"Zhang","year":"2020","journal-title":"Cancer Commun. (Lond.)"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0970","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ajpath.2021.01.002","article-title":"Host Cxcr2-dependent regulation of pancreatic cancer growth, angiogenesis, and metastasis","volume":"191","author":"Purohit","year":"2021","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107692","article-title":"Interleukin-8: a chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression","volume":"219","author":"Fousek","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0980","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/biom13010098","article-title":"Heparin-induced changes of vascular endothelial growth factor (VEGF(165)) structure","volume":"13","author":"Nemashkalova","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0985","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.3390\/cells10092231","article-title":"Roles of the FGF-FGFR signaling system in cancer development and inflammation","volume":"10","author":"Wiedlocha","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0990","doi-asserted-by":"crossref","first-page":"L191","DOI":"10.1152\/ajplung.00284.2003","article-title":"Heparin affects signaling pathways stimulated by fibroblast growth factor-1 and-2 in type II cells","volume":"287","author":"Newman","year":"2004","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb0995","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021106","article-title":"M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis","volume":"6","author":"Zhou","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1000","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1021\/jm201708h","article-title":"Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis","volume":"55","author":"Ferro","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1005","doi-asserted-by":"crossref","first-page":"13001","DOI":"10.1074\/jbc.M704531200","article-title":"Evidence that heparin saccharides promote FGF2 mitogenesis through two distinct mechanisms","volume":"283","author":"Goodger","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1010","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1111\/febs.12201","article-title":"Analysis of the fibroblast growth factor receptor (FGFR) signalling network with heparin as coreceptor: evidence for the expansion of the core FGFR signalling network","volume":"280","author":"Xu","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1015","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.3390\/ijms18102157","article-title":"TGF-\u03b2-induced endothelial-mesenchymal transition in fibrotic diseases","volume":"18","author":"Pardali","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1020","doi-asserted-by":"crossref","first-page":"16492","DOI":"10.1038\/s41598-020-73473-7","article-title":"Enhanced asthma-related fibroblast to myofibroblast transition is the result of profibrotic TGF-\u03b2\/Smad2\/3 pathway intensification and antifibrotic TGF-\u03b2\/Smad1\/5\/(8)9 pathway impairment","volume":"10","author":"Wnuk","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fcell.2020.00123","article-title":"Diverse role of TGF-\u03b2 in kidney disease","volume":"8","author":"Gu","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157340810791233033","article-title":"TGF-\u03b2: titan of lung fibrogenesis","volume":"6","author":"Yue","year":"2010","journal-title":"Curr. Enzym. Inhib."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3892\/ijmm.2021.4888","article-title":"Role and clinical significance of TGF-\u03b21 and TGF-\u03b2R1 in malignant tumors (review)","volume":"47","author":"Wang","year":"2021","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1040","doi-asserted-by":"crossref","first-page":"18000","DOI":"10.1074\/jbc.272.29.18000","article-title":"The interaction of the transforming growth factor-\u03b2s with heparin\/heparan sulfate is isoform-specific","volume":"272","author":"Lyon","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1045","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/glycob\/cwv064","article-title":"Structural determinants of heparin\u2013transforming growth factor-\u03b21 interactions and their effects on signaling","volume":"25","author":"Lee","year":"2015","journal-title":"Glycobiology"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1050","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1158\/1541-7786.MCR-11-0482","article-title":"Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis","volume":"10","author":"Pollari","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1055","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41419-019-1594-1","article-title":"IL-11 is essential in promoting osteolysis in breast cancer bone metastasis via RANKL-independent activation of osteoclastogenesis","volume":"10","author":"Liang","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1060","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10719-016-9742-7","article-title":"The role of heparins and nano-heparins as therapeutic tool in breast cancer","volume":"34","author":"Afratis","year":"2017","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1065","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000355837","article-title":"Heparin inhibits activation of latent transforming growth factor-\u03b21","volume":"92","author":"Lee","year":"2014","journal-title":"Pharmacology"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1070","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1042\/CS20040370","article-title":"The vascular endothelial growth factor (VEGF)\/VEGF receptor system and its role under physiological and pathological conditions","volume":"109","author":"Takahashi","year":"2005","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1075","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ijbiomac.2022.01.113","article-title":"Targeting the PDGF\/PDGFR signaling pathway for cancer therapy: a review","volume":"202","author":"Zou","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1080","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.biomaterials.2017.05.026","article-title":"A heparin conjugate, LHbisD4, inhibits lymphangiogenesis and attenuates lymph node metastasis by blocking VEGF-C signaling pathway","volume":"139","author":"Choi","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1085","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.biomaterials.2014.10.004","article-title":"LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways","volume":"37","author":"Chung","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1090","doi-asserted-by":"crossref","first-page":"7389","DOI":"10.1016\/j.actbio.2013.03.013","article-title":"Engineering strategies to control vascular endothelial growth factor stability and levels in a collagen matrix for angiogenesis: the role of heparin sodium salt and the PLGA-based microsphere approach","volume":"9","author":"d\u2019Angelo","year":"2013","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1095","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1038\/s41590-024-02006-5","article-title":"The diverse roles of neutrophils from protection to pathogenesis","volume":"25","author":"Herro","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1100","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/09537104.2021.1889310","article-title":"Platelets: bridging thrombosis and inflammation","volume":"32","author":"Rayes","year":"2021","journal-title":"Platelets"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1105","doi-asserted-by":"crossref","first-page":"10443","DOI":"10.1096\/fj.201900627R","article-title":"Heparinoid sevuparin inhibits Streptococcus-induced vascular leak through neutralizing neutrophil-derived proteins","volume":"33","author":"Rasmuson","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1110","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1165\/rcmb.2013-0338RC","article-title":"2-O, 3-O-desulfated heparin inhibits neutrophil elastase\u2013induced HMGB-1 secretion and airway inflammation","volume":"50","author":"Griffin","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cyto.2014.12.010","article-title":"Heparin inhibits the inflammatory response induced by LPS and HMGB1 by blocking the binding of HMGB1 to the surface of macrophages","volume":"72","author":"Li","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1120","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.tips.2024.05.008","article-title":"Targeting extranuclear histones to alleviate acute and chronic inflammation","volume":"45","author":"Nicolaes","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1125","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/0885066621992320","article-title":"The role of histones and heparin in sepsis: a review","volume":"37","author":"Zhang","year":"2022","journal-title":"J. Intensive Care Med."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233644","article-title":"Heparin and non-anticoagulant heparin attenuate histone-induced inflammatory responses in whole blood","volume":"15","author":"Hogwood","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1135","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12950-020-0238-7","article-title":"Different signaling pathways involved in the anti-inflammatory effects of unfractionated heparin on lipopolysaccharide-stimulated human endothelial cells","volume":"17","author":"Li","year":"2020","journal-title":"J. Inflamm."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1140","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.imbio.2014.10.008","article-title":"Unfractionated heparin attenuates LPS-induced IL-8 secretion via PI3K\/Akt\/NF-\u03baB signaling pathway in human endothelial cells","volume":"220","author":"Li","year":"2015","journal-title":"Immunobiology"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1145","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1007\/s11033-020-05435-1","article-title":"Role of PI3K\/AKT pathway in cancer: the framework of malignant behavior","volume":"47","author":"Jiang","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1150","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","article-title":"Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery","volume":"43","author":"Hu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1155","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12943-025-02243-8","article-title":"Inflammation in cancer: therapeutic opportunities from new insights","volume":"24","author":"Xie","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1160","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3332\/ecancer.2021.1258","article-title":"Aspirin and cancer survival: a systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers","volume":"15","author":"Elwood","year":"2021","journal-title":"ecancermedicalscience"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1165","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1170","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/CAD.0000000000000141","article-title":"Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice","volume":"25","author":"Kim","year":"2014","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1175","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jconrel.2014.12.015","article-title":"Antiangiogenic and anticancer effect of an orally active low molecular weight heparin conjugates and its application to lung cancer chemoprevention","volume":"199","author":"Kim","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1180","first-page":"ofaa563","article-title":"Role of low-molecular-weight heparin in hospitalized patients with severe acute respiratory syndrome coronavirus 2 pneumonia: a prospective observational study, open forum","volume":"7","author":"Falcone","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1185","first-page":"26","article-title":"Small dose of low molecular weight heparin improves the prognosis of elderly patients with severe pneumonia: a Meta-analysis of 1173 patients","volume":"32","author":"Yang","year":"2020","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1190","first-page":"825","article-title":"Effects of low molecular weight heparin on clinical efficacy, APACHE II score, and arterial blood gas analysis parameters in elderly patients with severe pneumonia","volume":"31","author":"Zhou","year":"2018","journal-title":"J. Math. Med."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1195","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/CM9.0000000000001923","article-title":"Low molecular weight heparin reduces arterial blood lactic acid content and increases estimated glomerular filtration rate in patients with moderate Covid-19 pneumonia","volume":"135","author":"Ma","year":"2022","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1200","doi-asserted-by":"crossref","first-page":"19902","DOI":"10.1038\/s41598-024-70064-8","article-title":"Nebulized enriched heparin improves respiratory parameters in patients with COVID-19: a phase I\/II randomized and triple-blind clinical trial","volume":"14","author":"Ramos da Silva Grillo","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1205","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2024.122930","article-title":"Heparin-azithromycin microparticles show anti-inflammatory effects and inhibit SARS-CoV-2 and bacterial pathogens associated to lung infections","volume":"348","author":"Anaya","year":"2025","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1210","first-page":"CD006774","article-title":"Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis","volume":"8","author":"Chande","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134259","article-title":"Orally administered enoxaparin ameliorates acute colitis by reducing macrophage-associated inflammatory responses","volume":"10","author":"Lean","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1220","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/10717544.2017.1324530","article-title":"Nanoparticle-based delivery enhances anti-inflammatory effect of low molecular weight heparin in experimental ulcerative colitis","volume":"24","author":"Yazeji","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1225","article-title":"Heparin-coated albumin nanoparticles for drug combination in targeting inflamed intestine","volume":"9","author":"Zhang","year":"2020","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1230","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.116660","article-title":"Mucoadhesive nanoparticles-based oral drug delivery systems enhance ameliorative effects of low molecular weight heparin on experimental colitis","volume":"246","author":"Yan","year":"2020","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1235","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2020.111851","article-title":"Enema based therapy using liposomal formulation of low molecular weight heparin for treatment of active ulcerative colitis: new adjunct therapeutic opportunity","volume":"121","author":"Ahmad","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1240","doi-asserted-by":"crossref","first-page":"eado7438","DOI":"10.1126\/sciadv.ado7438","article-title":"\u201cTwo-birds-one-stone\u201d oral nanotherapeutic designed to target intestinal integrins and regulate redox homeostasis for UC treatment","volume":"10","author":"Huang","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1245","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13017-024-00558-3","article-title":"Effectiveness and safety of low molecular weight heparin in the management of acute pancreatitis: a systematic review and meta-analysis","volume":"19","author":"Podda","year":"2024","journal-title":"World J. Emerg. Surg."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1250","article-title":"Efficacy of low-molecular-weight heparin in the treatment of severe acute pancreatitis: a comparative study at a tertiary health center","volume":"16","author":"Ca","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2022.106621","article-title":"Impact of low-molecular-weight heparin in the treatment of moderately severe and severe acute pancreatitis; a randomized, single blind, phase 3 control trial","volume":"101","author":"Patil","year":"2022","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1260","article-title":"Low molecular weight heparin decreases mortality and major complication rates in moderately severe and severe acute pancreatitis-a systematic review and meta-analysis","volume":"10","author":"Patoni","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106318","article-title":"Ultrasound-induced destruction of heparin-loaded microbubbles attenuates L-arginine-induced acute pancreatitis","volume":"180","author":"Lin","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1270","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.3390\/polym14122470","article-title":"Heparin protects severe acute pancreatitis by inhibiting HMGB-1 active secretion from macrophages","volume":"14","author":"Yang","year":"2022","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1275","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1200\/JOP.2015.004473","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"11","author":"Lyman","year":"2015","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1280","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jth.12070","article-title":"International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"11","author":"Farge","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1285","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1290","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/cells13030211","article-title":"A new synthesized dicarboxylated oxy-heparin efficiently attenuates tumor growth and metastasis","volume":"13","author":"Li","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1295","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.gene.2016.03.044","article-title":"Anti-tumor effects of bemiparin in HepG2 and MIA PaCa-2 cells","volume":"585","author":"Alur","year":"2016","journal-title":"Gene"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1300","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/jop.13563","article-title":"The effects of enoxaparin treatment in a xenograft mouse model of oral squamous cell carcinoma: a pilot study","volume":"53","author":"Ekici","year":"2024","journal-title":"J. Oral Pathol. Med."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1305","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jconrel.2014.12.015","article-title":"Antiangiogenic and anticancer effect of an orally active low molecular weight heparin conjugates and its application to lung cancer chemoprevention","volume":"199","author":"Kim","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1310","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1173634","article-title":"Heparins are potent inhibitors of ectonucleotide pyrophosphatase\/phosphodiesterase-1(NPP1)-a promising target for the immunotherapy of cancer","volume":"14","author":"Lopez","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1315","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1172\/JCI76566","article-title":"Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation","volume":"126","author":"Brennan","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1320","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007080","article-title":"Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer","volume":"11","author":"Quan","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1325","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1158\/1078-0432.CCR-22-2757","article-title":"Anticoagulants enhance molecular and cellular immunotherapy of cancer by improving tumor microcirculation structure and function and redistributing tumor infiltrates","volume":"29","author":"Wei","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1330","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.bcp.2015.07.013","article-title":"Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells","volume":"97","author":"Pfankuchen","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1335","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3390\/molecules22050728","article-title":"The impact of the low molecular weight heparin tinzaparin on the sensitization of cisplatin-resistant ovarian cancers-preclinical in vivo evaluation in xenograft tumor models","volume":"22","author":"Mueller","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1340","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.21873\/anticanres.13723","article-title":"Inhibition of PAR-1 receptor signaling by enoxaparin reduces cell proliferation and migration in A549 cells","volume":"39","author":"Alturkistani","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1345","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.matbio.2023.06.008","article-title":"Fibrolamellar carcinomas-growth arrested by paracrine signals complexed with synthesized 3-O sulfated heparan sulfate oligosaccharides","volume":"121","author":"Zhang","year":"2023","journal-title":"Matrix Biol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1350","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1538-7836.2004.00871.x","article-title":"A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer","volume":"2","author":"Altinbas","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1355","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0002-9343(90)90093-S","article-title":"Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels","volume":"89","author":"Edwards","year":"1990","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1360","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","article-title":"Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer","volume":"48","author":"Maraveyas","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1365","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.3390\/cancers13122884","article-title":"The impact of thromboprophylaxis on the survival of patients with advanced pancreatic cancer. The pancreatic cancer and tinzaparin (PaCT) study","volume":"13","author":"Karamouzis","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1370","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2016.34.15_suppl.8506","article-title":"Randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in completely resected non-small cell lung cancer patients: the NVALT-8 study","volume":"34","author":"Groen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1375","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s13233-016-4111-8","article-title":"Antiangiogenic actions of heparin derivatives for cancer therapy","volume":"24","author":"Hwang","year":"2016","journal-title":"Macromol. Res."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1380","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41416-018-0006-0","article-title":"A phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours","volume":"118","author":"Dredge","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1385","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ejca.2015.02.007","article-title":"PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples","volume":"51","author":"Winterhoff","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1390","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejmech.2016.05.052","article-title":"Recent advances in the discovery of heparanase inhibitors as anti-cancer agents","volume":"121","author":"Jia","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1395","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/ph18030396","article-title":"Expanding the role of heparin derivatives in oncology: from anticoagulation to antitumor activity","volume":"18","author":"Holail","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1400","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3109\/1061186X.2014.996760","article-title":"A low-molecular-weight heparin-coated doxorubicin-liposome for the prevention of melanoma metastasis","volume":"23","author":"Chen","year":"2015","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1405","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejps.2018.04.011","article-title":"Dose-reduction antiangiogenic curcumin-low molecular weight heparin nanodrugs for enhanced combinational antitumor therapy","volume":"119","author":"Xiao","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1410","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/polym12010043","article-title":"Redox-responsive heparin-chlorambucil conjugate polymeric prodrug for improved anti-tumor activity","volume":"12","author":"Andrgie","year":"2019","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1415","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jconrel.2021.06.019","article-title":"Dual mechanistic TRAIL nanocarrier based on PEGylated heparin taurocholate and protamine which exerts both pro-apoptotic and anti-angiogenic effects","volume":"336","author":"Choi","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1420","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ijbiomac.2020.12.043","article-title":"Heparin modified photosensitizer-loaded liposomes for tumor treatment and alleviating metastasis in phototherapy","volume":"168","author":"Cao","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1425","doi-asserted-by":"crossref","first-page":"55577","DOI":"10.1021\/acsami.1c18055","article-title":"Heparin-coated photosensitive metal-organic frameworks as drug delivery nanoplatforms of autophagy inhibitors for sensitized photodynamic therapy against breast cancer","volume":"13","author":"Sun","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1430","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jcis.2024.02.141","article-title":"Glycolysis-non-canonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment","volume":"665","author":"Qiao","year":"2024","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1435","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1007\/s11095-016-2010-5","article-title":"Emodin-loaded PLGA-TPGS nanoparticles combined with heparin sodium-loaded PLGA-TPGS nanoparticles to enhance chemotherapeutic efficacy against liver cancer","volume":"33","author":"Liu","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1440","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jconrel.2016.02.044","article-title":"Sigma receptor-mediated targeted delivery of anti-angiogenic multifunctional nanodrugs for combination tumor therapy","volume":"228","author":"Li","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1445","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jcis.2018.10.039","article-title":"pH-activatable polymeric nanodrugs enhanced tumor chemo\/antiangiogenic combination therapy through improving targeting drug release","volume":"536","author":"Xiong","year":"2019","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1450","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijbiomac.2019.05.031","article-title":"The utilization of low molecular weight heparin-poloxamer associated Laponite nanoplatform for safe and efficient tumor therapy","volume":"134","author":"Li","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1455","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jconrel.2023.03.017","article-title":"cRGD-targeted heparin nanoparticles for effective dual drug treatment of cisplatin-resistant ovarian cancer","volume":"356","author":"Liang","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1460","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijpharm.2017.02.051","article-title":"Gambogic acid grafted low molecular weight heparin micelles for targeted treatment in a hepatocellular carcinoma model with an enhanced anti-angiogenesis effect","volume":"522","author":"Yan","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1465","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.actbio.2018.05.050","article-title":"A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer","volume":"75","author":"Tian","year":"2018","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1470","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1016\/j.ijbiomac.2020.08.068","article-title":"Low molecular weight heparin modified bone targeting liposomes for orthotopic osteosarcoma and breast cancer bone metastatic tumors","volume":"164","author":"Wu","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1475","article-title":"Glycol-split heparin-linked prodrug nanoparticles target the mitochondrion apparatus for cancer metastasis treatment","volume":"19","author":"Sun","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1480","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijpharm.2017.10.055","article-title":"Self-assembled nanocomplex of PEGylated protamine and heparin-suramin conjugate for accumulation at the tumor site","volume":"535","author":"Park","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1485","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.117490","article-title":"Tumor microenvironment-responsive PEGylated heparin-pyropheophorbide-a nanoconjugates for photodynamic therapy","volume":"255","author":"Wu","year":"2021","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ijbiomac.2025.148054_bb1490","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.actbio.2023.04.016","article-title":"Stimuli-responsive heparin-drug conjugates co-assembled into stable nanomedicines for cancer therapy","volume":"164","author":"Fang","year":"2023","journal-title":"Acta Biomater."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025086118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025086118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T11:40:33Z","timestamp":1773142833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025086118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":298,"alternative-id":["S0141813025086118"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.148054","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multifaceted roles of heparin and its derivatives in inflammation and cancer: Mechanisms, clinical applications, and future directions","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.148054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"148054"}}